Hematology Times
|
LeukemiasDrug reformulation allows for increased dose in AML
Doctor examines child
Credit: Logan Tuttle Modifying the formulation of an anthracycline has allowed researchers to administer the drug at higher doses without increasing risks to patient safety, according to a study published in Blood. The investigators tested a liposomal formulation of daunorubicin (L-DNR) in pediatric patients with acute myeloid leukemia (AML). Patients were able to receive the drug at higher-than-standard doses, which resulted in improved survival, without experiencing higher rates of cardiotoxicity. [Read Article] RNA molecule protects HSCs
Hematopoietic stem cells
in the bone marrow Results of preclinical research indicate that microRNA-146a (miR-146a) acts as a critical regulator and protector of hematopoietic stem cells (HSCs) during chronic inflammation. And this suggests a deficiency of miR-146a may be an important cause of bone marrow failure and hematologic neoplasms, particularly myelodysplastic syndrome (MDS). Researchers came to this conclusion by developing a mouse model that lacks miR-146a. When subjected to a state . . . [Read Article] Macrophages provide new approach for cancer vaccines
Macrophage in a mouse
Source: Flickr Researchers say they’ve discovered another viable approach for cancer vaccines: using the macrophage pathway to program killer T cells against cancers. The team had previously shown that nearly all cancer cells use the molecule CD47 to escape from being eliminated by macrophages. The group also found that anti-CD47 antibodies, which can block CD47’s signal and enable macrophages to engulf cancer cells, inhibited the growth of various hematologic cancers and solid tumors. [Read Article] Risk of hematologic, other cancers after CT scans
Patient undergoing a CT scan
Credit: Angela Mary Butler A large, population-based study has provided additional insight into the risk of hematologic and solid tumor malignancies associated with CT scans. Previous research has suggested CT scans pose cancer risks, particularly following exposures in childhood. However, most studies have estimated risks indirectly, and some radiation experts have questioned the validity of these estimates. To provide more definitive data, John D. Mathews, MD, PhD, of the University of Melbourne in Australia . . . [Read Article] Tool simplifies complex cell data
Acute myeloid leukemia
cells in the bone marrow Scientists have developed computational software that allows them to visualize and interpret “high-dimensional” data produced by single-cell measurement technologies. The software—called visual interactive stochastic neighbor embedding (viSNE)—has particular relevance for cancer research, the team said. They used viSNE to study the bone marrow of patients with acute myeloid leukemia and found they could detect minimal residual disease (MRD) at extremely low levels. [Read Article] |
|